key: cord-0899234-b1fv5vj2
authors: Kaka, Anjum S.; MacDonald, Roderick; Linskens, Eric J.; Wilt, Timothy J.
title: Update Alert 2: Remdesivir for Adults With COVID-19
date: 2021-10-05
journal: Ann Intern Med
DOI: 10.7326/l21-0600
sha: 9e62a779da72e3d8e597b04b5a899eac81613cb4
doc_id: 899234
cord_uid: b1fv5vj2

nan

1 followed by 100 mg on days 2-5 in single daily infusions Intervention 2: Remdesivir, 10-day course (n=197) 200 mg on day 1 followed by 100 mg on days 2-10 in single daily infusions Inclusion criteria: patients ≥ 18 years (at all sites), or aged ≥ 12 and < 18 years of age weighing ≥ 40 kg (where permitted according to local law) currently hospitalized with SARS-CoV-2 infection confirmed by PCR test ≤ 4 days before randomization; radiographic evidence of pulmonary infiltrates and peripheral capillary oxygen saturation (SpO2) ≤ 94% or requiring supplemental oxygen at screening N=397 Age (years, median): 5-day group 61 10-day group 62 Gender (male): 5- Exclusion criteria: Pregnant or women who were breast feeding infants, ALT or AST >5 times the upper limit of the normal range, creatinine clearance < 50 mL/min using the Cockcroft-Gault formula for participants ≥ 18 years of age and Schwartz Formula for participants < 18 years of age; mechanically ventilated (including V-V ECMO) ≥ 5 days, or any duration of V-A ECMO; evidence of multiorgan failure; concurrent treatment with other agents with actual or possible direct acting antiviral activity against SARS-CoV-2 < 24 hours prior to study drug dosing; participant in any other clinical trial of an experimental treatment for COVID-19

Study Period/Length of Follow-up: 14 days (up to 30 days for adverse events)

Remdesivir 5-day median [IQR] 8 days [5] [6] [7] [8] [9] [10] [11] Remdesivir 10-day median [IQR] 9 days [6] [7] [8] [9] [10] [11] [12] Oxygen status on admission: Percent on no oxygen 14% Percent on supplemental oxygen 55% Percent on non-invasive ventilation 27% Percent on invasive ventilation 4% Inclusion criteria: ≥ 18 years (at all sites), or aged ≥ 12 and < 18 years of age weighing ≥ 40 kg (where permitted according to local law and approved by relevant review boards) currently hospitalized and requiring medical care for COVID-19; SARS-CoV-2 infection confirmed by PCR test ≤ 4 days before randomization; moderate COVID-19 pneumonia (peripheral capillary oxygen saturation (SpO2) >94% on room air radiographic evidence of pulmonary infiltrates) Exclusion criteria: Women who were pregnant or breast feeding infants, ALT or AST >5 times the upper limit of the normal range; creatinine clearance < 50 mL/min using the Cockcroft-Gault formula for participants ≥ 18 years of age and Schwartz Formula for participants < 18 years of age; mechanically ventilated at screening; concurrent treatment or planned concurrent treatment 

Serious adverse events

Remdesivir 10-day course may result in a small reduction versus SC (4) 

Remdesivir 10-day course versus placebo (2) (5), assessed as high risk of bias, did not impact the overall certainty of evidence or magnitude of effect ¶ Downgraded two levels for study limitations and imprecision (wide CIs) ** Downgraded two levels for imprecision and inconsistency † † Downgraded two levels for difficulty in interpreting precision and inconsistency. ‡ ‡ Downgraded to insufficient for difficulty in interpreting results (HR not reported for 5-day vs.10 day) and higher median with 10-day vs standard of care but reduction in time to recovery favors 10-day based on HR § § Downgraded two levels for imprecision and inconsistency ‖‖ Downgraded to insufficient for study limitations and imprecision (very wide CIs) 

ACTT-1 Study Group Members. Remdesivir for the treatment of Covid-19 -final report

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

Remdesivir for 5 or 10 days in patients with severe Covid-19

GS-US-540-5774 Investigators. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19. A randomized clinical trial

WHO Solidarity Trial Consortium. Repurposed antiviral drugs for Covid-19 -interim WHO Solidarity Trial Results

Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19: A Randomized Trial

Clinical outcomes of using remdesivir in patients with moderate to severe COVID-19: A prospective randomised study

‡ Severe disease was defined as participants meeting one or more of the following criteria: requiring invasive or non-invasive mechanical ventilation, requiring supplemental oxygen, an SpO2 ≤94% on room air, or respiratory rate ≥24 breaths per minute. § Defined as a two-point reduction in patients' admission status on a six-point ordinal scale, or live discharge from the hospital, whichever came first. The six-point scale was as follows: death=6; hospital admission for extracorporeal membrane oxygenation or mechanical ventilation=5; hospital admission for noninvasive ventilation or high-flow oxygen therapy=4; hospital admission for oxygen therapy (but not requiring high-flow or non-invasive ventilation)=3; hospital admission but not requiring oxygen therapy=2; and discharged or having reached discharge criteria (defined as clinical recovery-ie, normalization of pyrexia, respiratory rate <24 breaths per minute, saturation of peripheral oxygen >94% on room air, and relief of cough, all maintained for at least 72 h)=1 within 28 days after randomization ‖ Patients achieved clinical recovery if they no longer required oxygen support and medical care or were discharged from the hospital (improvement from a baseline score of 2 to 5 to a score of 6 or 7). ¶ Clinical improvement was defined as an improvement of two or more points from baseline on a predefined seven-point scale consisting of the following categories: 1, death; 2, hospitalized, receiving invasive mechanical ventilation or ECMO; 3, hospitalized, receiving noninvasive ventilation or high-flow oxygen devices; 4, hospitalized, requiring low-flow supplemental oxygen; 5, hospitalized, not requiring supplemental oxygen but receiving ongoing medical care (related or not related to Covid-19); 6, hospitalized, requiring neither supplemental oxygen nor ongoing medical care (other than that specified in the protocol for remdesivir administration); and 7, not hospitalized. ** Indicates newly identified sub-study Supplement were excluded from analyses ALT = alanine aminotransferase; AST = aspartate aminotransferase; ITT = intent-to-treat * For the open-label trial, blinding of study participants and study personnel was not feasible. This element was not considered in rating overall risk of bias. † Incomplete outcome data was rated high if more than 10% of participants randomized were not included in the analyses. ‡ Selective reporting was determined by comparing reported outcomes with outcomes specified in the Methods section. If a protocol paper was available, reported outcomes were compared with outcomes specified in the protocol. § Studies were rated low risk of bias if at least 3 elements were rated low and no additional elements were rated high. Studies were rated High risk of bias if at least 2 elements were rated high risk of bias. All other studies were rated Moderate risk of bias. ‖ Indicates newly identified sub-study.